The Turing test has had a free ride in science media for far too long, says an AI expert: In the view of Rensselaer philosopher and computer scientist Selmer Bringsjord, the iconic Turing test for human-like intelligence in computers is inadequate and easily gamed. Merely sounding enough like a human to fool people does not establish human-like intelligence. He proposes the much more challenging Lovelace test, based on an observation from computer pioneer Ada Lovelace (1815–1852) that true creativity is what distinguishes humans from machines. – Mind Matters News Further reading: No materialist theory of consciousness is plausible. All such theories either deny the very thing they are trying to explain, result in absurd scenarios, or end up requiring an Read More ›

There are numerous article out there right now indicating that the fatality ratio of this corona virus looks to be in the same range as that of a seasonal flu. Dr. Fauci keeps saying that he thinks this virus will be a seasonal flu. But, of course. Now, there’s a study by an Israeli scientist who tells us that this virus has its own pattern and that this patterns works itself out over a set period of time, lockdown or no. He marvels at the fear factor at work. It’s like a seasonal flu. He asks: was this exponential growth? His answer: no. (Was I not mocked for not understanding that we were dealing with exponential growth——–while I was looking Read More ›

Survivors speak: Voices count . . . and, pardon the interviwer. END

From this article: It’s important to note that HCQ, zinc, and azithromycin are very well understood drugs with clear safety profiles; they are widely available, generic, inexpensive, and can be scaled rapidly, including to the developing world… Our primary strategic objective must be to prevent ICU overwhelm, which on our current course is imminent in most states. It is an axiom of infectious diseases that treatment in earlier stages is more effective than treating advanced stages. Early COVID-19 treatment is more likely to prevent disease progression to critical status, radically lowering hospitalizations and CFR than inaction. Current clinical drug trials are mostly focused on treating late stages of disease, when immunologic damage is a dominant threat. We believe that trials Read More ›

Prof Raoult’s web site hosts an interesting map, under the title, “Pays où l’hydroxychloroquine est recommandée”: India, of course, has the further approval for prophylaxis. That’s significant, as talk on vaccines tends to point to 12 – 18 months and double-blind, placebo controlled tests in progress or about to start in the US look likely to take more than a year. Meanwhile, OWID tracks how time to double to current number of deaths — probably the best statistic — is continuing to stretch out: (Notice, the S-curves and driving impulses.) Likewise, we can see the daily cases clearly peaking (for THIS wave . . . notice, Wave 2 for China and even an uptick to a Wave 3): This is Read More ›